Learn about VE303, a potential first-in-class Live Biotherapeutic Product for preventing recurrent Clostridioides difficile ...

Johnson & Johnson is advancing Alzheimer’s research through precision medicine, focusing on tau-targeting therapies like ...

Discover the groundbreaking AI-based platform that designs peptides to target and destroy previously 'undruggable' ...

ITM announces positive Phase 3 results for ITM-11 in neuroendocrine tumours, paving the way for a potential new treatment ...

Glox Therapeutics secures £500K from a £3M fund to develop antibiotics targeting antimicrobial-resistant lung infections in ...

Casdozokitug, combined with atezolizumab and bevacizumab, shows durable responses and a 17.2% complete response rate in HCC ...

Rigel Pharmaceuticals has enrolled the first patient in a Phase I trial to evaluate fostamatinib as a treatment for sickle ...

New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

Learn about the gut-brain connection in mental health and how targeting serotonin in the gut could revolutionise ...

Cancer Research UK, Cytovation, and the Norwegian Cancer Society collaborate to advance treatment for adrenocortical ...